相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Integrated genomics of chemotherapy resistant ovarian cancer: A role for extracellular matrix, TGFbeta and regulating microRNAs
Jozien Helleman et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
EGFR and β1 integrins utilize different signaling pathways to activate Akt
Teet Velling et al.
EXPERIMENTAL CELL RESEARCH (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line
Atsuko Ogino et al.
CANCER RESEARCH (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
Kimihide Yoshida et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
A. Sutani et al.
BRITISH JOURNAL OF CANCER (2006)
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
Jeffrey A. Engelman et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2006)
Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck
C Willmore-Payne et al.
MODERN PATHOLOGY (2006)
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
Tania Cufer et al.
ANTI-CANCER DRUGS (2006)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib
F Koizumi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mutations and addiction to EGFR:: the Achilles 'heal' of lung cancers?
AF Gazdar et al.
TRENDS IN MOLECULAR MEDICINE (2004)
Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro
QY Lu et al.
CANCER LETTERS (2004)
Timeline - Gefitinib - a novel targeted approach to treating cancer
RS Herbst et al.
NATURE REVIEWS CANCER (2004)
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells
G Giannelli et al.
BRITISH JOURNAL OF CANCER (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells
HM Bill et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Extracellular matrix regulation of drug resistance in small-cell lung cancer
RC Rintoul et al.
CLINICAL SCIENCE (2002)
分享论文
